Subj : Neuralink's human trial ¨
To   : ALL
From : Mike Powell
Date : Wed Jan 31 2024 13:21:00

 ELON MUSK'S NEURALINK IMPLANTS BRAIN TECH IN HUMAN PATIENT FOR THE
FIRST TIME (2 MINUTE READ) [8]

 Neuralink implanted a device in a human for the first time on Sunday.
The patient is recovering well, according to a post on X by Elon Musk.
Neuralink is developing a brain implant that aims to help patients
with severe paralysis control external technologies using only neural
signals. The technology could help patients with severe degenerative
diseases communicate and interact with devices using their minds.
Neuralink has not disclosed how many human patients are involved in
its initial in-human trial.

 SCIENTISTS DOCUMENT FIRST-EVER TRANSMITTED ALZHEIMER'S CASES, TIED
TO NO-LONGER-USED MEDICAL PROCEDURE (8 MINUTE READ) [11]

 A decades-old treatment for a number of conditions that caused short
stature, which involved patients receiving growth hormone taken from
the brains of human cadavers, has been tied to some people as young as
in their 30s developing Alzheimer's disease. The treatment, which was
banned 40 years ago, transmitted unwanted proteins into recipients'
brains, including the beta-amyloid protein that later propagated into
the disease-causing plaques that are the hallmark of the disease.
These are the first documented cases of transferred Alzheimer's - the
disease is not usually contagious. The cadaveric growth hormone
treatment has been long replaced with a synthetic hormone treatment.

 SCIENTISTS THINK THEY'RE ON THE VERGE OF BREACHING THE BLOOD-BRAIN
BARRIER (3 MINUTE READ) [10]

 The brain and spinal cord are well protected by the blood-brain
barrier, which stops almost all drugs from entering the central
nervous system. Researchers at the University of Pennsylvania are
testing the delivery of lipid nanoparticles, fat-soluble packages that
can pass through the blood-brain barrier and carry proteins,
antibodies, and messenger RNA with them. The technique is able to pass
some drugs through the blood-brain barrier, but not all of the
medicine made it into brain cells when tested in living mice. The
researchers are using a new in vitro model that will help guide the
future development of brain-targeted treatments.

 NEW GITHUB COPILOT RESEARCH FINDS 'DOWNWARD PRESSURE ON CODE QUALITY'

 A recent study on the quality and maintainability of AI-assisted code
found disconcerting trends for maintainability. The percentage of
lines that are reverted or updated less than two weeks after being
authored is projected to double this year compared to a pre-AI
baseline. Using AI coding tools is strongly correlated with mistake
code being pushed to repositories. While AI may be able to produce
code faster, the code it produces needs to be cleaned up, potentially
removing the benefits of fast code generation.

 WHAT BIG TECH LAYOFFS SUGGEST FOR THE INDUSTRY (7 MINUTE READ) [14]

 Microsoft's layoffs last year were worrisome because the company has
a very good track record of predicting how its business will grow or
shrink. Microsoft's business is incredibly diversified to the point
where it can be pretty representative of the B2B tech industry, minus
advertising. The company's decision to initiate layoffs suggested that
the tech industry would stall growth-wise. Microsoft's announcements
could have caused other large tech companies to follow suit and
announce their own layoffs.


 * SLMR 2.1a * 
--- SBBSecho 3.14-Linux
 * Origin: capitolcityonline.net * Telnet/SSH:2022/HTTP (1:2320/105)

.